Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma
Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma
复制标题
DOI：
10.1111/j.1349-7006.2003.tb01438.x
复制
发表时间：
2003-03-01
期刊：
影响因子：
5.7
通讯作者：
Kobayashi, T
中科院分区：
文献类型：
--
作者：
Ito, A;Tanaka, K;Kobayashi, T
免疫疗法（IT）已成为一种公认的治疗方式。我们以前报道过使用磁性纳米颗粒的细胞内热疗（IH）诱导抗肿瘤免疫。我们进行了这些研究，以研究IT和IH对黑色素瘤的联合作用。磁铁矿阳离子脂质体（MCL）具有正表面电荷，并且由于磁滞损耗而在交变磁场（AMF）中产生热量。将MCL注射到C57 BL/6小鼠的B16黑色素瘤结节中，对其进行AMF 30 min。肿瘤处的温度达到43 ℃，并通过控制磁场强度来维持。IH后24 h，将白细胞介素-2（IL-2）或粒细胞巨噬细胞集落刺激因子（GM-CSF）直接注射入黑色素瘤内。将小鼠分为六组：I组（对照）、II组（IH）、III组（IL-2）、IV组（GM-CSF）、V组（IH+IL-2）和VI组（IH+GM-CSF）。在第V组和第VI组的小鼠中观察到肿瘤完全消退（分别为75%（6/ 8）和40%（4/10）的小鼠），而在其他组的小鼠中未观察到肿瘤消退。本研究支持在晚期恶性肿瘤患者中联合使用IT和IH（使用MCL）。（Cancer Sci 2003; 94：308-313）。
Immunotherapy (IT) has become an accepted therapeutic modality. We previously reported that intracellular hyperthermia (IH) using magnetic nanoparticles induces antitumor immunity. We undertook these studies in order to study the combined effects of IT and IH on melanoma. Magnetite cationic liposomes (MCLs) have a positive surface charge and generate heat in an alternating magnetic field (AMF) due to hysteresis loss. MCLs were injected into a B16 melanoma nodule in C57BL/6 mice, which were subjected to AMF for 30 min. The temperature at the tumor reached 43degreesC and was maintained by controlling the magnetic field intensity. At 24 h after IH, interieukin-2 (IL-2) or granulocyte macro phage-colony stimulating factor (GM-CSF) was injected directly into the melanoma. Mice were divided into six groups: group I (control), group II (IH), group III (IL-2), group IV (GM-CSF), group V (IH+IL-2), and group VI (IH+GM-CSF). Complete regression of tumors was observed in mice of groups V and VI (75% (6/ 8) and 40% (4/10) of the mice, respectively), while no tumor regression was observed in mice of the other groups. This study supports the combined use of IT and IH using MCLs in patients with advanced malignancies. (Cancer Sci 2003; 94: 308-313).